Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hoogkamp-Korstanje, J. A. A.
Right arrow Articles by Roelofs-Willemse, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoogkamp-Korstanje, J. A. A.
Right arrow Articles by Roelofs-Willemse, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 31-39
© 2000 The British Society for Antimicrobial Chemotherapy

Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates

J. A. A. Hoogkamp-Korstanje* and J. Roelofs-Willemse

Department of Medical Microbiology, University Hospital St Radboud, University of Nijmegen, Geert Grooteplein 24, 6500 HB Nijmegen, The Netherlands

The in vitro activity of moxifloxacin was compared with that of 15 antibacterial agents against 513 Gram-positive microorganisms. The MIC90 (mg/L) of moxifloxacin was 0.06 for quinolone-susceptible Staphylococcus aureus and Staphylococcus epidermidis, 0.12 for Streptococcus pyogenes and Streptococcus agalactiae; 0.25 for Streptococcus pneumoniae, Streptococcus mitis, Streptococcus bovis, Streptococcus anginosus and Actinomyces pyogenes; 0.5 for Streptococcus sanguis and Listeria monocytogenes, 2 for Corynebacterium jekeium and Bifidobacterium bivius. Over 50% of Enterococcus faecalis, Enterococcus faecium, quinolone-resistant staphylococci, Nocardia steroides and Clostridium difficile were susceptible to 2 mg/L moxifloxacin. Moxifloxacin and trovafloxacin demonstrated comparably high activity towards Gram-positive cocci; moxifloxacin and clinafloxacin were most active against Gram-positive bacilli.

*Corresponding author. Tel: +31-24-36-14-356; Fax: +31-24-35-40-216; E-mail: j.hoogkamp{at}mmb.azn.nl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
E. Mutlu, A. J. Wroe, K. Sanchez-Hurtado, J. S. Brazier, and I. R. Poxton
Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland
J. Med. Microbiol., July 1, 2007; 56(7): 921 - 929.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. L. Frank, E. J. Reichert, K. E. Piper, and R. Patel
In Vitro Effects of Antimicrobial Agents on Planktonic and Biofilm Forms of Staphylococcus lugdunensis Clinical Isolates
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 888 - 895.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. Malincarne, M. Ghebregzabher, M. V. Moretti, A. M. Egidi, B. Canovari, G. Tavolieri, D. Francisci, G. Cerulli, and F. Baldelli
Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty
J. Antimicrob. Chemother., May 1, 2006; 57(5): 950 - 954.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Vera-Cabrera, E. Y. Ochoa-Felix, G. Gonzalez, R. Tijerina, S. H. Choi, and O. Welsh
In Vitro Activities of New Quinolones and Oxazolidinones against Actinomadura madurae
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1037 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Sauermann, R. Gattringer, W. Graninger, A. Buxbaum, and A. Georgopoulos
Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics
J. Antimicrob. Chemother., January 1, 2003; 51(1): 53 - 57.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. W. Kaatz, V. V. Moudgal, and S. M. Seo
Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus
J. Antimicrob. Chemother., December 1, 2002; 50(6): 833 - 838.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Dridi, J. Tankovic, B. Burghoffer, F. Barbut, and J.-C. Petit
gyrA and gyrB Mutations Are Implicated in Cross-Resistance to Ciprofloxacin and Moxifloxacin in Clostridium difficile
Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3418 - 3421.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. Portier, J. Filipecki, P. Weber, G. Goldfarb, D. Lethuaire, and J.-P. Chauvin
Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, open-label, randomized study
J. Antimicrob. Chemother., February 1, 2002; 49(2): 337 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Ackermann, Y. J. Tang, R. Kueper, P. Heisig, A. C. Rodloff, J. Silva Jr., and S. H. Cohen
Resistance to Moxifloxacin in Toxigenic Clostridium difficile Isolates Is Associated with Mutations in gyrA
Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2348 - 2353.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.